Research Activity
NS Pharma’s Viltepso Fails Confirmatory Phase III Trial for Duchenne Muscular Dystrophy Treatment
Viltepso, NS Pharma, Duchenne muscular dystrophy, RACER53 study, viltolarsen, FDA approval, confirmatory trial, phase III trial, DMD treatment
J&J Adjusts Dosing Strategy for Actinium Prostate Cancer Drug Following Early Study Setbacks
J&J, Johnson & Johnson, actinium prostate cancer drug, capped dosing, flexible dosing, patient deaths, early study, clinical trial, cancer treatment, drug development.
Semaglutide Significantly Improves Cardiovascular Health and Reduces Mortality Risk in Kidney Disease Patients, Novo Reports
Semaglutide, Novo, cardiovascular health, kidney disease, mortality risk, clinical trial
Nuvation Bio Unveils Groundbreaking Cancer Drug Data from AnHeart Acquisition in China
Nuvation Bio, AnHeart, cancer drug, pivotal data, China, acquisition, clinical trials
ASCO24: Nimbus Unveils Promising Early Data for Next-Generation HPK1 Blocker in IO Therapies
ASCO24, Nimbus, Next-Generation IO Therapies, HPK1 Blocker, Early Data, Cancer Treatment, Immuno-Oncology, Clinical Trials.
Exscientia Streamlines Operations, Prioritizes AI-Driven Drug Discovery
Exscientia, AI-generated pipeline, drug discovery, staff reduction, operational efficiency, biotechnology, pharmaceutical industry
Tango Pauses Clinical Trials of Promising Solid Tumor Treatment Due to Liver Toxicity Concerns
Tango Therapeutics, solid tumor treatment, clinical trials, liver toxicity, drug development, cancer research, treatment side effects, patient safety.
Takeda Ventures into Molecular Glue Degraders with Degron Collaboration
Takeda, Degron, molecular glue degraders, pharmaceutical collaboration, targeted protein degradation, drug discovery.
Bicycle Therapeutics Gears Up for Future Milestones with $555 Million Capital Infusion
Bicycle Therapeutics, funding, catalysts, biotechnology, drug development, clinical trials, investors, capital infusion, milestones.
Evotec Discontinues Gene Therapy Operations, Shuts Down Austria Facility
Evotec, gene therapy, Austria, facility closure, strategic decision, business operations, research and development, biotechnology